A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

NCT ID: NCT02138162

Last Updated: 2014-05-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-08-31
• Study Completion Date: 2014-03-31

Brief Summary

The influence of severely diminished liver function on the metabolism, safety, and tolerability of a single oral dose of enzalutamide in a group of 8 men. The results are compared to the data gained from 8 age- and BMI-matched men with normal liver function.

Detailed Description

Screening takes place between Day -22 and Day -2, and subjects are admitted to the clinic on Day -1. Each subject receives a single oral dose of enzalutamide on Day 1, under fasted conditions. They are discharged on Day 7; ambulant visits take place until Day 50. An End of Study Visit (ESV) occurs 7-10 days after the last PK sampling or early withdrawal.

Full PK profiles are obtained for enzalutamide, metabolite 1 of enzalutamide (M1) and metabolite 2 of enzalutamide (M2) up to 1176 hours (Day 50) after administration.

Safety assessments are performed throughout the study. For subjects with severe hepatic impairment, additional Child-Pugh classification and laboratory safety tests (including liver function tests) are performed regularly after administration.

Conditions

Severe Hepatic Impairment; Normal Hepatic Function

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

1:Single dose of enzalutamide in hepatically impaired subjects

Single dose of enzalutamide

Group Type: EXPERIMENTAL

enzalutamide

Intervention Type: DRUG

oral

2:Single dose of enzalutamide in healthy subjects

Single dose of enzalutamide

Group Type: EXPERIMENTAL

enzalutamide

Intervention Type: DRUG

oral

Interventions

enzalutamide

oral

Intervention Type: DRUG

Other Intervention Names

ASP9785,; MDV3100,; Xtandi

Eligibility Criteria

Inclusion Criteria

• Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control starting at Screening and continue throughout the study period and for 90 days after the final study drug administration.
• Male subject must not donate sperm starting at Screening and throughout the study period and for 90 days after the final study drug administration.
• Subject has a Body Mass Index (BMI) range of 18.5 - 34.0 kg/m2 inclusive. The subject weighs at least 50 kg [at Screening].

• Subject has a Child-Pugh classification Class C (severe, 10 to 15 points).

• Age- and BMI-matched to subjects with severe liver hepatic impairment.

Exclusion Criteria

• Subject has known or suspected hypersensitivity to enzalutamide, or any components of the formulation used.
• Subject has history of seizure or any condition that may predispose to seizure. Also history of loss of consciousness or transient ischemic attack within 12 months of enrollment (Day 1 visit).
• Subject has used grapefruit (or grapefruit containing products) or marmalade in the week prior to admission to the clinical unit (Day -1), as reported by the subject.

• Subject has any of the liver function tests above the upper limit of normal.

• Subject has fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period.
• Subject has surgical porto-systemic shunts, including TIPSS (Trans-jugular intrahepatic portosystemic shunt).
• Subject has presence of severe hepatic encephalopathy (grade > 2).
• Subject has advanced ascites.
• Subject has esophageal variceal bleeding in the medical history (within 6 months before Day -1).
• Subject has thrombocyte level below 40x109 /L and /or hemoglobin below 90 g/L.
• Subject has significant renal dysfunction (creatinine clearance below 50 mL/min, estimated according to the method of Modification of Diet in Renal Disease (MDRD) formula).
• Subject has had previous liver transplantation.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 69 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Medivation, Inc.

INDUSTRY

Sponsor Role: collaborator

Astellas Pharma Europe B.V.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Monitor

Role: STUDY_DIRECTOR

Astellas Pharma Europe B.V.

Locations

Comac Medical Ltd.

Sofia, , Bulgaria

Countries

Bulgaria

Other Identifiers

2012-004858-29

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

9785-CL-0404

Identifier Type: -

Identifier Source: org_study_id